Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Sales and Divestitures: 2016-2022

Historic Gains from Sales and Divestitures for Editas Medicine (EDIT) over the last 7 years, with Dec 2022 value amounting to $286,642.

  • Editas Medicine's Gains from Sales and Divestitures fell 9.46% to $210,701 in Q2 2023 from the same period last year, while for Jun 2023 it was $210,701, marking a year-over-year decrease of 9.46%. This contributed to the annual value of $286,642 for FY2022, which is 7.25% up from last year.
  • Editas Medicine's Gains from Sales and Divestitures amounted to $286,642 in FY2022, which was up 7.25% from $267,268 recorded in FY2021.
  • In the past 5 years, Editas Medicine's Gains from Sales and Divestitures ranged from a high of $304,638 in FY2020 and a low of $99,919 during FY2019.
  • Over the past 3 years, Editas Medicine's median Gains from Sales and Divestitures value was $286,642 (recorded in 2022), while the average stood at $286,183.
  • In the last 5 years, Editas Medicine's Gains from Sales and Divestitures crashed by 68.98% in 2018 and then skyrocketed by 204.88% in 2020.
  • Yearly analysis of 5 years shows Editas Medicine's Gains from Sales and Divestitures stood at $243,225 in 2018, then crashed by 58.92% to $99,919 in 2019, then soared by 204.88% to $304,638 in 2020, then declined by 12.27% to $267,268 in 2021, then rose by 7.25% to $286,642 in 2022.